Please assess the completion status of the following clinical trial:

Trial Title: Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Previously untreated stage IA, IB, IIA or IIB classical Hodgkin Lymphoma~* Non-bulky disease defined as less than 10 cm in maximal diameter~* Measurable disease greater than or equal to 1.5 cm~* ECOG performance status of 0 or 2~* Willing to use 2 effective forms of birth control~Exclusion Criteria:~* No prior chemotherapy or radiotherapy for Hodgkin lymphoma~* Not receiving any other investigational agents~* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to Adriamycin, Vinblastine, Dacarbazine or brentuximab~* No pre-existing grade 3 or greater neuropathy~* No uncontrolled intercurrent illness~* Not pregnant or breastfeeding~* No history of a different malignancy unless disease free for at least one year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Brentuximab Vedotin in combination with Adriamycin, Vinblastine and Dacarbazine

Based on this trial design, predict the completion outcome and termination type (if applicable).